173 related articles for article (PubMed ID: 33919902)
1. Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids.
Pengnam S; Plianwong S; Patrojanasophon P; Radchatawedchakoon W; Yingyongnarongkul BE; Opanasopit P; Charoensuksai P
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33919902
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy.
Hemati M; Haghiralsadat F; Yazdian F; Jafari F; Moradi A; Malekpour-Dehkordi Z
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1295-1311. PubMed ID: 30033768
[TBL] [Abstract][Full Text] [Related]
3. Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1.
Pengnam S; Opanasopit P; Rojanarata T; Yingyongnarongkul BE; Thongbamrer C; Plianwong S
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896184
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
5. Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.
Suo A; Qian J; Xu M; Xu W; Zhang Y; Yao Y
Mater Sci Eng C Mater Biol Appl; 2017 Jul; 76():659-672. PubMed ID: 28482576
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells.
Sharma G; Tyagi AK; Singh RP; Chan DC; Agarwal R
Breast Cancer Res Treat; 2004 May; 85(1):1-12. PubMed ID: 15039593
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
8. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
9. siRNA Targeting Mcl-1 Potentiates the Anticancer Activity of Andrographolide Nanosuspensions via Apoptosis in Breast Cancer Cells.
Pengnam S; Charoensuksai P; Yingyongnarongkul BE; Saeeng R; Uludağ H; Patrojanasophon P; Opanasopit P; Plianwong S
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745769
[TBL] [Abstract][Full Text] [Related]
10. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
11. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
12. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
[TBL] [Abstract][Full Text] [Related]
13. Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect.
Han C; Zhang C; Ma T; Zhang C; Luo J; Xu X; Zhao H; Chen Y; Kong L
Acta Biomater; 2018 Sep; 77():268-281. PubMed ID: 30006311
[TBL] [Abstract][Full Text] [Related]
14. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
15. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.
Chiu CF; Lin YQ; Park JM; Chen YC; Hung SW; Chiu CC; Chang CF
Biomed Pharmacother; 2020 Aug; 128():110309. PubMed ID: 32505820
[TBL] [Abstract][Full Text] [Related]
16. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
[TBL] [Abstract][Full Text] [Related]
17. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
18. Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy.
Tavano L; Muzzalupo R; Mauro L; Pellegrino M; Andò S; Picci N
Langmuir; 2013 Oct; 29(41):12638-46. PubMed ID: 24040748
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]